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Want to try a fun social experiment? 
Mention the term behavioral research 
to any scientist and watch their reaction. 
Some ﬁ  nd the idea of behavioral research 
daunting, while others think the ﬁ  eld isn’t 
really a science, just the mere act of watch-
ing a subject’s performance while making 
a few checkmarks on a clipboard. For those 
that have run behavioral experiments, we 
understand the theory and importance 
behind the research, and have an appre-
ciation for a thorough and coherent experi-
mental study.
In the last decade, the ﬁ  eld of Neuroscience 
has been more accepting of behavior as 
a necessary part of the empirical studies 
that previously contained only cellular or 
histological ﬁ   ndings. Science in general, 
is moving toward translational research 
(Zerhouni, 2005), so being able to show 
how the cellular or chemical changes affect 
the organism as a whole, has become a high 
priority. Transgenic mice have contributed 
enormous amounts of data to every sub cat-
egory of neuroscience. The great minds of 
Biomedical Scientists are able to splice cells, 
taking out genes or introducing new ones in, 
but they need the expertise of a Behavioral 
Scientist in order to assess the changes to 
the organism that can not tell us what it is 
thinking or feeling.
So let’s explore this further and start 
by asking, where does behavioral testing 
begin, and why is it important? The answers 
to both depend on the study you are con-
ducting, especially when you are consider-
ing adding a substance into the mix that 
can alter physiology. Genetically mutated 
mice are engineered to determine the effects 
of a speciﬁ  c gene, or more commonly, in 
an effort to mimic human symptoms of 
disease. Pharmaceutical companies and 
toxicologists ﬁ   nd themselves needing to 
comprehensively assess drug efﬁ  cacy in a 
high throughput fashion, something that 
can take years to do in both human and 
non-human primates over the course of the 
lifespan. The development of the transgenic 
mouse, allows pre-clinical screening, on a 
mass level in a comparatively short period 
of time. This has created a major concern 
for drug research studies in terms of accu-
rately determining what changes can be 
attributed to the drug as opposed to the 
changes in behavior due to the transgene 
manipulation. Therefore, prior to using 
any transgenic mouse model of disease, 
the researcher needs to know what changes 
the gene  modiﬁ  cation has caused in the 
mouse model, and places a great empha-
sis on the art of behavioral phenotyping. 
If you know what behaviors are “normal” 
for your mouse model, then you can deter-
mine what tests to use in a battery of assess-
ments, including what home cage behaviors 
are important in your selection of data 
points. Take a current Alzheimer’s disease 
(AD) model as an example, the Tg 2576 for 
which the background strain is C57BL/6J. 
This particular AD mouse model carries the 
human gene for amyloid precursor protein 
(APP), which is responsible for the forma-
tion of AD like plaques in humans (Hsiao 
et al., 1996). Bred from a mouse that has the 
recessive gene Pdebrd1, severe visual impair-
ments (Gimenez and Montoliu, 2001) and 
deafness (Johnson et al., 1997) are com-
mon in these animals after 9  months of 
age. Additionally, after a period of time the 
animals begin to lose their hair and whisk-
ers, and barber (over groom) themselves. It 
is necessary that these key characteristics are 
known prior to designing/conducting any 
behavioral task that uses auditory or visual 
cues for the animal to complete, as results 
might imply cognitive deﬁ  cits.
HOME CAGE BEHAVIORS
Home cage behaviors in laboratory animal 
research are important because they are the 
best measure scientist’s have, of the natu-
ral occurring behavior of the animal being 
studied. Since testing occurs in the animal’s 
home environment, there are no confounds 
associated with human interference, testing 
protocol, or   behavioral changes associated 
with moving the   animal to another testing 
apparatus, just basic naturalistic observa-
tions of normal laboratory animal behav-
ior. Typical home cage behavior monitoring 
includes measurements of circadian rhythms 
in addition to locomotor and stereotypic 
(pathologically repetitive) behaviors, all of 
which will be changed if a pharmaceutical 
intervention has an adverse effect on the ani-
mal or if the genetic mutation has changed 
the mouse model (Bordone et  al., 2007; 
Dickinson et al., 2009; Jackson et al., 2009). 
Excessive grooming is a good example of 
why you would want to identify the pheno-
typic behaviors of your model prior to drug 
treatment. A pharmaceutical company may 
interpret barbering behaviors in the Tg 2576 
model as skin sensitivity due to the treat-
ment, when in fact it is merely a typical char-
acteristic for this mouse model. Therefore, 
not only can you obtain information about 
phenotypic behaviors by including home 
cage analysis in a study, you’re also capable 
of collecting data about drug efﬁ  cacy.
Many are discouraged from including 
home cage analysis within a study due 
to the time constraints of monitoring 
cages 24/7, not to mention the complex-
ity of numerous cages. However, just as 
the technology has assisted with the GLP 
compliance issues, it can also assist with 
animal testing issues. Roughan et al. (2009) 
used an automated behavioral recognition 
program to monitor pain and analgesic 
effects in mice while in the home cage 
after surgery. Results suggest that the pro-
gram was as good as human monitoring. 
The program also provided investigators 
measurements that would have been oth-
erwise impossible for a human scorer such 
as distance traveled throughout the cages 
and durations of all the various events. 
In a Huntington’s disease mouse model, 
Steele et al. (2007) found that an automated 
home cage analysis found signiﬁ  cant dif-
ferences between Tg and Wt mice 6 weeks 
prior to the onset of the disease. Clinical 
phenotypes of human Huntington’s such Thompson and Micheli  Pre-clinical pharmacovigilance
as the rest-wake   abnormalities, not previ-
ously identiﬁ  ed in a mouse model, was also 
observed using the automated system. The 
inclusion of automated high throughput 
technology in lieu of human observation 
makes this monitoring as efﬁ  cient as pos-
sible. Identifying subtle phenotypic behav-
ioral changes early in experimentation, and 
ones closely related to human behaviors, 
would streamline the pre-clinical drug 
efﬁ  cacy process and increase pre-  clinical 
pharmacovigiliance.
BEHAVIORAL BATTERIES
Once the mouse model has been prop-
erly phenotyped and any drug or genetic 
effects ascertained via home cage observa-
tion, neurobehavioral assessments must be 
completed. In very speciﬁ  ed studies, one or 
two tests that target a particular brain region 
for assessment may be enough. However 
in most high throughput toxicology and 
drug studies, it is more important to do an 
overall assessment, to determine all impair-
ments or enhancements due to treatment, 
drug or otherwise. Perturbations in sensory 
processing resulting from genetic alterations 
or drug effects may not be identiﬁ  ed from 
just a couple of tasks, leading researchers to 
misinterpret the assessments. If a particu-
lar test relies on visual inputs for instance, 
such as the radial arm maze, and the model 
has poor visual acuity, then learning and 
memory may appear impaired (Garcia 
et al., 2004). If a behavioral battery were to 
be utilized in this case, learning and memory 
deﬁ  cits might not be diagnosed, as results 
from other tasks such as olfactory discrimi-
nation would not demonstrate cognitive 
deﬁ  cits. A comprehensive battery of tests 
is a recommended procedure to accurately 
determine the behavioral proﬁ  le of a par-
ticular mouse model in any drug study. Not 
only is a battery of tests suggested, but also 
the pre-clinical phase should examine early 
effects, long-term effects, and lifespan effects 
of the treatment. These data would be the 
most pertinent in studies being translated 
into clinical models of the same design. In 
the long run, these behavioral studies at 
the pre-clinical stage will ensure that drugs 
progress to clinical trials in the fastest, safest, 
and most effective manner possible. Though 
the inclusion of more data may seem to 
lengthen studies, it would strengthen safety. 
While many scientists look at CNS disor-
ders and drugs from a cellular level, we are 
dealing with diseases and side effects that 
manifest themselves behaviorally. Therefore, 
it is imperative that we look at them from a 
behavioral standpoint, and conduct research 
in a responsible and inclusive manner when 
it comes to drug development.
CONCLUSION
Using an automated home cage behavioral 
assessment to identify any adverse effects, 
early and throughout treatment, would be 
cost effective and efﬁ  cient for drug com-
panies. Overall, home cage behavioral 
measures, along with toxicology reports, 
behavioral assessments, and histology, 
gives researchers the most comprehensive 
information for pre-clinical screening. For 
the toxicologist this means more accu-
rately targeted molecules, and mass data 
points for preliminary screening; for non- 
researchers, this means less danger to the 
participants in clinical trials, and safer more 
effective drugs delivered to the public more 
efﬁ  ciently. Stringent pre-clinical measures 
over the rodents’ lifespan (approximately 
2 years), would increase pre-clinical phar-
macovigilance, and decrease potential 
adverse drug effects to the human popula-
tion (Maennl, 2008).
REFERENCES
Bordone, L., Cohen, D., Robinson, A., Motta, M. C., van 
Veen, E., Czopik, A., Steele, D. A., Crowe, H., Marmor, 
S., Luo, J., Gu, W., and Guarente, L. (2007). SIRT1 
transgenic mice show phenotypes resembling calorie 
restriction. Aging Cell 6, 759–767.
Dickinson, A. L., Leach, M. C., and Flecknell, P. A. (2009). 
The analgesic effects of oral paracetamol in two 
strains of mice undergoing vasectomy. Lab. Anim. 
43, 357–361.
Garcia, M., Gordon, M., Hutton, M., Lewis, J., McGowan, 
E., Dickey, C., Morgan, D., and Arendash, G.W. (2004). 
Retinal degeneration (rd) gene seriously impairs spa-
tial cognitive performance in normal and Alzheimer’s 
transgenic mice. Neuroreport 15, 73–77.
Gimenez, E., and Montoliu, L. (2001). A simple polymer-
ase chain reaction assay for genotyping the retinal 
degeneration mutation (Pdebrd1) in FVB/N-derived 
transgenic mice. Lab. Anim. 35, 153–156.
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, 
Y., Younkin, S., Yang, F., and Cole, G. (1996). Correlative 
memory deﬁ  cits, Abeta elevation, and amyloid plaques 
in transgenic mice. Science 274, 99–102.
Jackson, W. S., Borkowski, A. W., Fass, H., Steele, A. D., 
King, O. D., Watson, N., Jasanoff, A., and Lindquist, 
S. (2009). Spontaneous generation of prion infectiv-
ity in fatal familial insomnia knockin mice. Neuron 
63, 438–450.
Johnson, K. R., Erway, L. C., Cook, S. A., Willott, J. F., and 
Qing, Y. Z. (1997). A major gene affecting age-relationed 
hearing loss in C57BL/6J mice. Hear. Res. 114, 83–92.
Maennl, U. (2008). Pharmacovigilance: a company-wide 
challenge. Appl. Clin. Trials 17, 50–58.
Roughan, J. V., Wright-Williams, S. L., and Flecknell, P. A. 
(2009). Automated analysis of postoperative behavior: 
assessment of HomeCageScan as a novel method to 
rapidly identify pain and analgesic effects in mice. 
Lab. Anim. 43, 17–26.
Steele, A. D., Jackson, W. S., King, O. D., and Lindquist, 
S. (2007). The power of automated high-resolution 
behavior analysis revealed by its application to mouse 
models of Huntington’s and prion diseases. PNAS 
104, 1983–1988.
Zerhouni, E. A. (2005). Translational and clinical   science – 
time for a new vision. N. Engl. J. Med. 353, 1621–1623.
Received: 02 December 2009; accepted: 01 March 2010; 
published online: 22 March 2010.
Citation: Thompson JH and Micheli TL (2010) Behavioral 
assessments for pre-clinical pharmacovigilance. Front. 
Neurosci. 4:27. doi: 10.3389/fnpha.2010.00003
This article was submitted to Frontiers in Neuropharmacology, 
a specialty of Frontiers in Neuroscience.
Copyright © 2010 Thompson and Micheli. This is an 
open-access article subject to an exclusive license agreement 
between the authors and the Frontiers Research Foundation, 
which permits unrestricted use, distribution, and reproduc-
tion in any medium, provided the original authors and 
source are credited.
Frontiers in Neuroscience  | Neuropharmacology    March  2010 | Volume  4 | Article  27 | 2